Clinical Trials
44 trialsI-SPY
QuantumLeap Healthcare Collaborative
SPiReL
Sunnybrook Health Sciences Centre
NAVIGATE
Bayer
ATEZOGIST
Centre Leon Berard
CONGRATS
Institut Bergonié
IGNYTE-ESO
USWM, LLC (dba US WorldMeds)
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
AflacST1502
Emory University
Pan-MSI-ACSE
UNICANCER
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
University of California, San Diego
BETA-PRIME
EpicentRx, Inc.
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
ImmunityBio, Inc.
UVA-Gen001
University of Virginia
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
National Institutes of Health Clinical Center (CC)
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
ALpha-T
Hoffmann-La Roche
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
ABRADES
Grupo Espanol de Investigacion en Sarcomas
COPELIA
University of Manchester
CAPTIVE
DNAtrix, Inc.
Poly-ICLC
Oncovir, Inc.
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Children's Hospital of Philadelphia
ReACT
Celldex Therapeutics
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
GW572016 to Treat Recurrent Malignant Brain Tumors
National Institutes of Health Clinical Center (CC)
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
University of Michigan Rogel Cancer Center
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
National Institutes of Health Clinical Center (CC)
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
SCRI Development Innovations, LLC
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
InSightec
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Memorial Sloan Kettering Cancer Center
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Doxo
University Hospital Muenster
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Caphosol in Sarcoma Patients With Mucositis
M.D. Anderson Cancer Center
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
Fred Hutchinson Cancer Center
The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors
National Institutes of Health Clinical Center (CC)